HSG 2021: UNMASKING HD. The 28th Annual Meeting of the Huntington Study Group
HSG 2021: UNMASKING HD. The 28th Annual Meeting of the Huntington Study Group - event link
Pepinemab – Anti-SEMA4D Antibody Treatment for Huntington’s Disease
CTAD 2021 presentation: SEMA4D blocking antibody, pepinemab , is a novel potential treatment for neurodegenerative disease: clinical proof of concept in HD supports clinical development in AD
SITC 2021 poster: Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84)
2022 HNSCC Symposium Poster: Phase 1/2 study of pepinemab in combination with pembrolizumab as first-line treatment of advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84)
2022 CHDI poster: Combination anti-SEMA4D immunotherapy and HTT-lowering ASO provide benefit beyond either individual therapy in preclinical HD mouse model